摘要:
When liquefying sludge, e.g as in U.S. Pat. No. 6,808,636, the combination of temperature, pH, and shearing, is synergistic. Described here is a system that provides for collating test sampling and full-scale data inputs, recording achieved results and the engineering parameters that achieved those particular results. The data is presented in e.g a table format, which assists design engineers to zero-in on the combinations of parameters that will likely give the desired results.
摘要:
Disclosed herein are cylinder forming apparatuses for making nonwoven webs. In one embodiment, a cylinder forming apparatus has a first source configured to dispense a first fluid flow stream, and a second source configured to dispense a second fluid flow stream, wherein at least the first fluid flow stream comprises a fiber; an arcuate mixing partition downstream from the one or more sources, the arcuate mixing partition positioned between the first and second flow streams, the apparatus defining one or more openings that permit fluid communication between the two flow streams; and a cylindrical receiving region situated downstream from the sources and proximal to the first flow stream and designed to receive at least a combined flow stream and form a nonwoven web by collecting fiber from the combined flow stream. Methods of using the apparatuses are also disclosed.
摘要:
Provided are compounds that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes mellitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity of glucokinase or which can be treated by activating glucokinase.
摘要:
Provided are compounds of Formula (I): wherein R2, R3, R13, L and D2 are as defined in the specification, which are useful in the treatment and/or prevention of diseases or disorders mediated by deficient levels of glucokinase activity or which can be treated by activating glucokinase including, but not limited to, diabetes mellitus, impaired glucose tolerance, IFG (impaired fasting glucose) and IFG (impaired fasting glycemia), as well as other diseases and disorders such as those discussed herein.
摘要:
Methods and apparatuses for forming a nonwoven web are described herein. The apparatus includes a mixing partition defining one or more openings therein that permit fluid communication between two fluid flow streams, at least one of which includes a fiber. The apparatus also includes an enclosed region surrounding at least a portion of the mixing partition. The enclosed region is adapted to provide an applied pressure to a fluid flow stream to urge the stream through one or more of the openings in the mixing partition. The apparatus also includes a receiving region designed to receive at least a combined flow stream and form a nonwoven web by collecting fiber from the combined flow stream.
摘要:
This invention relates to an improved and scalable process for the preparation of substantially pure palonosetron and its acid addition salts, in particular hydrochloride (I) which comprises of, (a) converting intermediate (IIa) as such or as its freebase (II) to a crude mixture of diastereomeric palonosetrons (VIII) or (VIIIa) contaminated with varying amounts of unconverted intermediate (II) or (IIa) via hydrogenation under pressure with an appropriately chosen hydrogenation catalyst in an suitable organic solvent. (b) making the resulting crude mixture of diastereomeric palonosetrons (VIII) or (VIIIa) contaminated with varying amounts of unconverted intermediate (II) or (IIa) substantially free from (II) or (IIa) via halogenation reaction. (c) Finally, converting the resulting diastereomeric palonosetron (VIII) or its hydrochloride (VIIIa) substantially free from intermediate (II) or (IIa) to the desired palonosetron hydrochloride (I) in substantially pure form via selective crystallization from a suitable single or mixture of organic solvents.
摘要:
Provided are compounds of formula I that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes meilitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity of glucokinase or which can be treated by activating glucokinase.
摘要:
This invention relates to an improved and scalable process for the preparation of substantially pure palonosetron and its acid addition salts, in particular hydrochloride (I) which comprises of, (a) converting intermediate (IIa) as such or as its freebase (II) to a crude mixture of diastereomeric palonosetrons (VIII) or (VIIIa) contaminated with varying amounts of unconverted intermediate (II) or (IIa) via hydrogenation under pressure with an appropriately chosen hydrogenation catalyst in an suitable organic solvent. (b) making the resulting crude mixture of diastereomeric palonosetrons (VIII) or (VIIIa) contaminated with varying amounts of unconverted intermediate (II) or (IIa) substantially free from (II) or (IIa) via halogenation reaction. (c) Finally, converting the resulting diastereomeric palonosetron (VIII) or its hydrochloride (VIIIa) substantially free from intermediate (II) or (IIa) to the desired palonosetron hydrochloride (I) in substantially pure form via selective crystallization from a suitable single or mixture of organic solvents.
摘要:
Sewage sludge is dewatered to a cake-like state. The viscosity of the sludge is lowered by admixing a quantity of urea, urea-ammonium-nitrate, or other nitrogen-containing material, in with the dewatered sludge. The treatment also removes pathogens, and renders the product suitable for use as a fertilizer.
摘要:
Provided are compounds of Formula (I): wherein R2, R3, R13, L and D2 are as defined in the specification, which are useful in the treatment and/or prevention of diseases or disorders mediated by deficient levels of glucokinase activity or which can be treated by activating glucokinase including, but not limited to, diabetes mellitus, impaired glucose tolerance, IFG (impaired fasting glucose) and IFG (impaired fasting glycemia), as well as other diseases and disorders such as those discussed herein.